studi
object
describ
compar
background
clinic
manifest
diseas
cours
infecti
etiolog
pneumon
acut
exacerb
pnae
vs
nonpneumon
acut
exacerb
npae
copd
design
prospect
observ
studi
set
tertiari
univers
medic
center
southern
israel
patient
twentythre
hospit
pnae
hospit
npae
includ
studi
pair
sera
obtain
hospit
test
serolog
pathogen
signific
chang
antibodi
titer
level
consid
diagnost
result
signific
differ
found
two
group
paramet
relat
copd
comorbid
clinic
type
exacerb
significantli
differ
group
compar
npae
patient
pnae
lower
po
valu
hospit
admiss
p
higher
rate
abrupt
onset
p
icu
admiss
p
invas
mechan
ventil
p
mortal
p
longer
hospit
stay
p
conclus
communityacquir
pneumonia
common
among
patient
hospit
acut
exacerb
copd
gener
manifest
sever
clinic
laboratori
paramet
pnae
compar
npae
viral
pneumococc
etiolog
common
rate
atyp
pathogen
similar
therapeut
signific
find
investig
c
opd
common
diseas
prolong
chronic
cours
diseas
episod
acut
exacerb
often
occur
episod
deleteri
effect
patient
qualiti
life
necessit
util
healthcar
servic
includ
hospit
time
although
definit
acut
exacerb
copd
aecopd
problemat
gener
diagnos
categor
basi
clinic
criteria
increas
short
breath
andor
increas
editori
comment
see
page
amount
purul
sputum
communityacquir
pneumonia
cap
infecti
diseas
broad
spectrum
sever
among
cap
patient
highest
sever
diseas
requir
hospit
copd
common
comorbid
two
diagnos
cap
aecopd
come
togeth
copd
patient
acquir
aecopd
caus
cap
clinic
manifest
episod
meet
accept
criteria
diagnosi
aecopd
cap
determin
case
chest
radiograph
obtain
pulmonari
infiltr
found
number
publish
articl
cap
patient
copd
small
prospect
multicent
spanish
studi
hospit
cap
among
patient
copd
investig
despit
import
studi
acut
episod
investig
viewpoint
cap
aecopd
comparison
case
case
aecopd
without
cap
context
larg
studi
infecti
etiolog
patient
hospit
aecopd
databas
creat
hospit
broad
rang
infecti
etiolog
diagnos
serolog
hospit
frequenc
distribut
infecti
etiolog
found
studi
present
discuss
previou
public
aim
present
studi
use
databas
evalu
episod
cap
patient
copd
aspect
aecopd
describ
compar
background
clinic
manifest
diseas
cours
infecti
etiolog
episod
patient
pneumon
acut
exacerb
pnae
nonpneumon
acut
exacerb
npae
copd
patient
hospit
aecopd
period
novemb
march
intern
medicin
intens
care
ward
soroka
medic
center
beersheva
israel
met
inclus
criteria
gave
consent
particip
includ
studi
first
hospit
studi
period
includ
well
repeat
hospit
aecopd
patient
studi
popul
hospit
took
place
least
month
initi
one
patient
recruit
studi
one
repeat
hospit
includ
studi
data
particular
patient
studi
approv
helsinki
committe
research
human
be
soroka
medic
center
particip
gave
inform
consent
particip
inclus
criteria
studi
group
fulfil
follow
five
condit
age
year
chronic
airway
obstruct
determin
spirometri
month
prior
hospit
within
month
follow
hospit
fev
valu
expect
fev
fvc
ratio
smoke
histori
least
packyear
increas
short
breath
signific
increas
sputum
product
new
expector
purul
sputum
increas
sputum
purul
week
prior
hospit
hospit
period
prior
present
hospit
patient
aecopd
hospit
decis
emerg
depart
physician
without
intervent
part
investig
everi
h
research
assist
visit
intern
medicin
intens
care
ward
identifi
patient
hospit
interim
met
inclus
criteria
studi
patient
agre
particip
studi
interview
concern
respiratori
diseas
regular
treatment
receiv
smoke
habit
complaint
symptom
current
acut
episod
first
meet
blood
sampl
ml
drawn
serolog
test
blood
sampl
centrifug
shortli
drawn
serum
frozen
temperatur
serolog
test
conduct
addit
relev
medic
administr
data
collect
medic
record
discharg
hospit
patient
invit
followup
appoint
pulmonari
clinic
soroka
medic
center
week
admiss
hospit
clinic
followup
data
collect
cours
convalesc
abnorm
event
may
occur
follow
discharg
hospit
meet
arteri
blood
sampl
obtain
ambient
pressur
spirometri
perform
patient
second
convalescencephas
serum
sampl
obtain
meet
serolog
test
sampl
handl
exactli
manner
previou
acutephas
sampl
patient
whose
hospit
period
extend
week
rehospit
time
schedul
followup
appoint
serum
sampl
drawn
hospit
patient
consid
stabl
condit
first
followup
appoint
week
hospit
invit
addit
followup
appoint
includ
spirometri
arteri
blood
ga
test
month
later
order
analyz
result
spirometr
measur
patient
stabl
respiratori
condit
well
diagnos
perman
obstruct
disturb
spirometri
inclus
criterion
definit
spirometri
conduct
purpos
vast
major
patient
clinic
followup
appoint
week
hospit
test
could
perform
occas
patient
stabl
condit
criteria
perman
airway
obstruct
assess
basi
previou
spirometri
perform
patient
stabl
condit
within
month
prior
hospit
followup
month
later
patient
spirometri
followup
demonstr
suffici
degre
airway
obstruct
withdrawn
studi
patient
underw
one
spirometr
test
period
begin
month
hospit
end
month
discharg
best
result
use
spirometr
test
conduct
experienc
technician
use
vitalograph
compact
instrument
vitalograph
buckingham
uk
calibr
begin
work
day
predict
valu
fev
calcul
accord
accept
european
valu
arteri
blood
ga
determin
present
result
also
conduct
patient
stabl
condit
obtain
time
definit
spirometri
test
done
arteri
blood
obtain
punctur
brachial
radial
arteri
test
immedi
blood
ga
system
radiomet
copenhagen
denmark
hospit
chest
radiograph
obtain
patient
still
emerg
depart
studi
purpos
week
radiograph
analyz
separ
senior
pulmonologist
senior
radiologist
radiograph
interpret
least
one
expert
pneumonia
classifi
stage
suspect
pneumonia
patient
underw
repeat
radiograph
clinic
followup
week
hospit
pair
radiograph
patient
acut
phase
convalesc
phase
interpret
separ
expert
pneumonia
diagnos
expert
independ
report
pulmonari
infiltr
acutephas
radiograph
disappear
retreat
significantli
followup
radiograph
case
two
expert
agre
consid
pneumonia
purpos
studi
patient
die
hospit
pneumonia
diagnos
presenc
typic
infiltr
admiss
chest
radiograph
present
previou
radiograph
etiolog
workup
studi
base
exclus
serolog
test
serolog
test
conduct
identifi
pathogen
known
infecti
agent
upper
lower
respiratori
tract
diagnos
serolog
method
pair
sera
patient
test
run
case
serolog
test
seven
respiratori
tract
virus
mycoplasma
pneumonia
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
conduct
use
enzym
immunoassay
method
microimmunofluoresc
serolog
use
identif
legionella
spp
signific
chang
antibodi
level
titer
specif
pathogen
acutephas
convalescencephas
serum
sampl
consid
diagnost
infect
pathogen
light
requir
patient
pair
sera
obtain
includ
final
data
analys
method
kit
criteria
use
serolog
diagnos
describ
detail
previou
public
result
analyz
use
statist
softwar
epi
info
epidemiolog
program
offic
center
diseas
control
prevent
atlanta
ga
test
equival
serv
compar
proport
group
analysi
varianc
done
compar
continu
variabl
among
two
group
statist
signific
set
p
studi
consist
hospit
aecopd
among
differ
copd
patient
period
case
convalescencephas
serum
sampl
obtain
mean
sd
interv
day
rang
day
first
sampl
obtain
begin
hospit
sinc
etiolog
diagnos
studi
base
chang
antibodi
leveltit
acutephas
convalescencephas
sera
includ
final
analys
studi
nine
hospit
convalescencephas
serum
obtain
one
hospit
includ
found
polyclon
respons
pathogen
test
hospit
patient
includ
final
analyz
studi
popul
hospit
patient
treat
cours
hospit
system
corticosteroid
hospit
chest
radiograph
classifi
acutephas
imag
suspect
pneumonia
radiograph
classifi
pneumonia
one
expert
basi
pair
radiograph
acut
phase
convalesc
phase
hospit
pair
chest
radiograph
classifi
two
examin
pneumonia
consid
studi
purpos
hospit
differ
patient
design
pnae
group
studi
patient
pneumonia
right
side
patient
left
side
patient
bilater
patient
pneumon
infiltr
homogen
patient
nonhomogen
patient
one
lobe
involv
pneumon
process
hospit
among
differ
patient
copd
design
npae
group
studi
tabl
present
comparison
data
patient
pnae
patient
npae
includ
demograph
data
baselin
spirometri
arteri
blood
ga
test
result
patient
stabl
condit
rate
chronic
steroid
therapi
rate
copd
complic
rate
influenza
pneumococc
vaccin
rate
chronic
comorbid
signific
differ
observ
variabl
two
group
tabl
present
comparison
clinic
express
exacerb
arteri
po
pco
level
admiss
two
studi
group
compar
npae
group
pnae
group
significantli
higher
rate
abrupt
onset
acut
exacerb
fever
acut
exacerb
crepit
lung
auscult
sever
hypoxemia
signific
differ
distribut
exacerb
accord
classif
anthonisen
et
al
two
group
clear
trend
higher
rate
type
exacerb
pnae
group
tabl
present
comparison
rate
invas
mechan
ventil
admiss
intens
care
durat
hospit
mortal
cours
recoveri
follow
discharg
hospit
two
group
first
four
paramet
marker
sever
acut
exacerb
pnae
group
significantli
sever
result
contrast
signific
differ
found
two
group
two
paramet
relat
cours
recoveri
acut
exacerb
follow
discharg
hospit
pnae
hospit
npae
hospit
least
one
infecti
etiolog
ae
identifi
serolog
test
significantli
higher
rate
viral
etiolog
pnae
group
especi
relat
parainfluenza
viru
type
adenoviru
pnae
group
also
significantli
higher
rate
bacteri
etiolog
particularli
pneumococc
differ
group
rate
atyp
bacteri
etiolog
compar
npae
group
vari
small
significantli
lower
percentag
patient
pnae
group
infecti
etiolog
identifi
serolog
test
one
etiolog
agent
mix
etiolog
found
patient
pnae
patient
patient
npae
repres
respect
patient
least
one
etiolog
agent
identifi
p
signific
ns
two
hospit
blood
cultur
find
posit
admiss
one
patient
pnae
blood
cultur
find
posit
pneumonia
also
posit
serolog
pathogen
patient
also
posit
serolog
test
result
parainfluenza
viru
type
adenoviru
pneumonia
one
patient
nape
group
blood
cultur
find
posit
streptococcu
miti
patient
serolog
test
result
also
posit
adenoviru
tabl
combin
clinic
symptom
typic
aecopd
develop
cap
bring
question
whether
justifi
diagnos
episod
aecopd
name
articl
express
posit
take
question
even
though
issu
controversi
accord
american
thorac
societi
standard
cap
exclud
diagnosi
aecopd
accord
british
thorac
societi
guidelin
copd
patient
cap
receiv
diagnosi
aecopd
recent
review
treatment
aecopd
studi
relat
aecopd
pneumonia
exclud
studi
anthonisen
et
al
connor
et
al
pneumonia
exclud
still
anoth
studi
sever
pneumonia
exclud
final
one
studi
pneumonia
list
exclud
studi
conduct
outpati
basi
chest
radiograph
obtain
routin
everi
patient
aecopd
semant
controversi
led
state
cap
patient
copd
clinic
manifest
aecopd
call
pneumon
aecopd
cap
patient
copd
other
decis
prefer
approach
exclud
patient
cap
diagnosi
aecopd
stem
two
follow
primari
consider
patient
clinic
express
episod
complet
meet
accept
criteria
aecopd
chest
radiographi
one
know
cap
present
justif
elimin
diagnosi
aecopd
appropri
note
patient
pneumon
exacerb
therebi
strengthen
therapeut
signific
combin
event
aecopd
episod
take
place
treat
commun
framework
outpati
basi
framework
chest
radiograph
routin
obtain
exclus
cap
practic
altern
comparison
demograph
data
clinic
background
pnae
group
npae
group
show
signific
differ
paramet
reflect
sever
baselin
airway
obstruct
baselin
ga
exchang
signific
differ
chronic
comorbid
contrast
statist
signific
differ
found
paramet
reflect
clinic
laboratori
sever
acut
episod
expect
differ
demonstr
sever
exacerb
pnae
group
note
differ
base
group
mean
patientbypati
analysi
paramet
show
substanti
number
patient
npae
group
sever
valu
pnae
patient
signific
find
opinion
clinic
laboratori
sever
aecopd
serv
reliabl
predictor
cap
acut
episod
similarli
clinic
type
exacerb
predict
whether
acut
diseas
caus
cap
import
find
studi
frequenc
distribut
infecti
etiolog
two
group
issu
prefer
method
determin
infecti
etiolog
respiratori
infect
gener
cap
aecopd
particular
complic
detail
discuss
would
beyond
scope
articl
factor
brought
us
choos
serolog
method
diagnost
method
studi
detail
discuss
previou
public
among
etiolog
test
two
virus
known
caus
infect
patient
copd
miss
coronaviru
rhinoviru
caus
common
cold
serolog
diagnosi
two
virus
particularli
difficult
includ
studi
howev
least
concern
rhinoviru
rate
patient
copd
infect
requir
hospit
low
compar
virus
anoth
respiratori
pathogen
conspicu
miss
list
etiolog
chlamydophila
chlamydia
pneumonia
pathogen
recogn
import
etiolog
agent
cap
includ
origin
list
etiolog
test
studi
howev
dataanalysi
stage
case
hospit
antibodi
titer
c
pneumonia
chang
signifi
cantli
pair
sera
antibodi
type
test
believ
feasibl
diagnos
acut
infect
pathogen
basi
high
unchang
titer
particularli
problemat
patient
copd
known
high
preval
chronic
infect
pathogen
diagnos
high
antibodi
titer
circumst
prefer
exclud
etiolog
despit
obviou
problem
associ
solut
reason
assum
least
patient
defin
studi
agent
identifi
infect
one
pathogen
miss
list
etiolog
aecopd
infect
expect
pneumococc
etiolog
identifi
pnae
group
common
etiolog
group
interest
rate
pneumococc
etiolog
ident
rate
found
previou
studi
similar
method
use
test
hospit
patient
cap
patient
copd
even
surpris
interest
ident
find
present
studi
rate
pneumococc
etiolog
report
spanish
studi
evalu
cap
etiolog
patient
copd
ident
found
even
though
studi
use
spectrum
diagnost
method
total
differ
use
present
studi
opinion
ident
rate
pneumococc
etiolog
two
studi
lend
support
robust
find
furthermor
see
ident
indirect
convinc
proof
reliabl
serolog
method
diagnos
pneumococc
infect
comparison
find
studi
spanish
studi
point
substanti
differ
viral
etiolog
identifi
patient
studi
compar
miniscul
rate
spanish
studi
atyp
bacteri
agent
also
found
much
lower
rate
spanish
studi
compar
base
knowledg
sensit
variou
method
use
studi
assum
differ
relat
viral
atyp
bacteri
etiolog
stem
high
sensit
method
use
studi
addit
convalesc
serum
sampl
obtain
patient
studi
great
import
serolog
diagnosi
viral
atyp
bacteri
etiolog
two
import
bacteri
etiolog
h
influenza
catarrhali
identifi
studi
much
lower
rate
previous
publish
studi
cultur
methodolog
use
identifi
caus
organ
aecopd
studi
two
bacteria
especi
h
influenza
identifi
predomin
organ
explan
result
present
studi
immunologicserolog
reaction
two
bacteria
strain
specif
serolog
assay
two
bacteria
util
antigen
deriv
nonhomolog
strain
therefor
underestim
role
infect
two
bacteria
exacerb
limit
serolog
method
relat
two
bacteria
particularli
import
point
view
frequenc
distribut
etiolog
aecopd
found
studi
therapeut
conclus
may
deriv
point
view
frequenc
distribut
etiolog
pnae
group
compar
npae
group
signific
differ
preval
etiolog
extent
would
justifi
base
differ
therapeut
strategi
aecopd
presenc
absenc
cap
american
thorac
societi
guidelin
manag
adult
cap
recent
publish
base
among
other
two
import
observ
confirm
number
studi
past
decad
one
observ
rel
high
preval
atyp
pathogen
among
caus
cap
observ
notuncommon
possibl
one
pathogen
mix
infect
particip
pathogenesi
cap
viewpoint
two
observ
find
present
studi
indic
similar
rate
atyp
etiolog
group
absenc
signific
differ
rate
mix
infect
two
group
even
though
rate
higher
pnae
group
find
rais
specul
question
whether
make
sens
recommend
antibiot
therapi
patient
aecopd
without
cap
import
question
test
studi
design
specif
address
issu
conclud
cap
common
among
patient
hospit
aecopd
usual
caus
exacerb
sever
clinic
laboratori
paramet
rate
atyp
etiolog
similar
group
therapeut
implic
find
investig
